Position in EXEL
as of Jun 30, 2026
· filed Jul 30, 2026
Position Value
$1,020,296
+$325,307 QoQ
Shares Held
18,752
+15.7% QoQ
Ownership
0.008%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#337
of 751 holders
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 20%
Shared 0%
None 80%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Chicago Partners Investment Group LLC holds $16,750,273 across 43 Biotechnology names. EXEL ranks #6 (6.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TSHA |
Taysha Gene Therapies, Inc.
|
222,347 | $1,514,183 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,209 | $1,377,399 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
5,326 | $1,283,406 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,455 | $1,219,472 | |
| 5 | CING |
Cingulate Inc.
|
188,429 | $1,030,706 | |
| 6 | EXEL |
Exelixis, Inc.
This page
|
18,752 | $1,020,296 | |
| 7 | RPRX |
Royalty Pharma plc
|
14,923 | $836,732 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
12,109 | $692,876 |
All Filings in EXEL
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,020,296 | 18,752 | Shares | Sole | 2026-07-30 | |
| 2026-03-31 | $694,989 | 16,204 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $690,848 | 15,762 | Shares | Sole | 2026-01-28 | |
| 2025-09-30 | $370,337 | 8,967 | Shares | Sole | 2025-10-30 | |
| 2025-06-30 | $321,651 | 7,297 | Shares | Sole | 2025-07-29 | |
| 2024-12-31 | $238,294 | 7,156 | Shares | Sole | 2025-01-24 | |
| No filing history on record for this holder in this stock. | ||||||